Recently, researchers developed a chlorotoxin-based CAR with the peptide as targeting domain that efficiently targeted tumors with heterogenous expression of GBM-associated antigens such as IL13Rα2, HER2, and EGFR [62]. This evidence concerns the gene IL13RA2 and glioblastoma.